Longevity scientist David Sinclair is preparing to test an oral drug mixture, code-named SL-100, for whole-body rejuvenation. This initiative is part of a $101 million XPrize competition aimed at restoring individuals to an earlier apparent age. The drug aims to achieve epigenetic reprogramming across the body, a significant advancement from previous gene therapy trials focused on specific organs like the eyes. While Sinclair is optimistic, some experts express caution regarding the efficacy and concentration of chemical reprogramming agents. AI
IMPACT Potential to accelerate research into age-related diseases and therapies, though not directly AI-related.
RANK_REASON A prominent scientist is planning human trials for a novel rejuvenation drug as part of a major competition. [lever_c_demoted from significant: ic=4 ai=0.1]
Read on MIT Technology Review →
- Betterhumans
- Harvard Medical School
- James Clement
- Life Biosciences
- Peter Diamandis
- Soxogen
- XPRIZE Foundation
AI-generated summary · Google Gemini · from 5 sources. How we write summaries →
